Accessibility Help | Sitemap | Contact Us | Customer Support CALL 1-800-275-4524
United States Change Country
Careers | Investor Relations | News & Media | Events | KCI Recycling | About KCI
Home  |  Conditions  |  Products  |  Clinical Evidence  |  Education and Training  |  For Patients  |  Customer Support  |  Suppliers
You are here: Home > About KCI > News & Media > KCI's V.A.C.Via™ Therapy System to be Listed on U.K. Drug Tariff

KCI's V.A.C.Via™ Therapy System to be Listed on U.K. Drug Tariff

Released : June 30th 2011

V.A.C.Via System Has the Potential to Save National Health Service Money; Provides Benefits to Patients and Clinicians

KCI, Leader in Advanced Wound Care Solutions

SAN ANTONIO—June 30, 2011— Kinetic Concepts, Inc. (NYSE:KCI) today announced that its groundbreaking V.A.C.Via Negative Pressure Wound Therapy System has been granted reimbursement status and will be listed on the U.K. Drug Tariff beginning August 1, 2011. The V.A.C.Via Therapy System is a next-generation negative pressure wound therapy (NPWT) solution that offers clinicians and patients an off-the-shelf, portable healing technology with the proven benefits of V.A.C.® Therapy. The technology provides the healing power of V.A.C.® Therapy for low- to moderate-exudating wounds while offering simplicity, mobility and convenience to both physicians and patients.

"The economic benefits of the V.A.C.Via System are clear: patients are able to leave the hospital in a quicker and more seamless manner by eliminating waiting in the hospital just for therapy to arrive. This presents a benefit to both patients and providers," said Mike Genau, global president, KCI's Active Healing Solutions business unit. "This decision by the U.K. health authorities to reimburse KCI's V.A.C.Via System in the home will offer a tremendous advantage to patients and the medical community alike, helping to reduce costs and provide positive clinical outcomes."

With the V.A.C.Via System, therapy may be initiated in a variety of care settings, from the hospital to outpatient clinics. For patients, the V.A.C.Via System's portable, discreet, easy-to-operate design enables them to return to home or work without therapy interruption. For providers, this for-sale device that can be kept on the shelf at facilities may allow for earlier patient discharge, potentially reducing length of stay. The V.A.C.Via System provides all the benefits of traditional V.A.C.® Therapy for less complex wounds with minimal to moderate levels of wound exudates in a disposable form. It is an example of an acute therapy that can also be delivered in the home, as outlined in the Department of Health white paper Equity to Excellence: Liberating the NHS.

"The development of this device really enables a patient-centered approach to care. We can now treat patients from the comfort of their own home in combination with state-of-the-art care," said Dr. Toby Richards, vascular surgeon, University College Hospital, London. "Because it is a portable and disposable system, the V.A.C.Via System reduces National Health Service costs and frees up hospital beds, relieving pressure on the system. Ultimately, it is better for patients to be at home recovering with their families and daily activities."

The V.A.C.Via System is powered by Vortis Technology, which is an extremely small, innovative negative pressure therapy pump that allows for delivery of V.A.C.® Therapy in a more portable, virtually silent and discreet manner. The V.A.C.Via System technology is built on the foundations of V.A.C.® Therapy, the only wound care technology substantiated by 25 randomized controlled trials and more than 550 peer-reviewed articles. The V.A.C.Via System takes that science and makes the entire process — hospital to home — simpler, more mobile and outcome-driven.

Advancing KCI's position as a leader in NPWT, the V.A.C.Via System is part of a broader product portfolio strategy to extend the healing benefits of negative pressure therapy to more patients and conditions.

For more information about KCI please visit

About KCI

Kinetic Concepts, Inc. (NYSE:KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world. The company employs approximately 7,100 people and markets its products in more than 20 countries. For more information about KCI and how its products are changing the practice of medicine, visit


Kinetic Concepts, Inc.
Media Relations: for journalists only.
Investors Relations: for Investor Relations inquiries.

  • KCI Express
  • Share on
  • Share on Twitter
  • Visit our YouTube page

Important Message for Patients

Terms of Use | Privacy Notice | Safe Harbor Policy | Contact Us | News Feed

Copyright © 1998 - 2013 KCI Licensing, Inc. All Rights Reserved.    DSL# 09-03-193
The information included in this Web site has been prepared for and is intended for viewing exclusively within the United States of America. This Web site contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult individual country sites for approved uses and any applicable restrictions.